MDM2 and brain neoplasm: This way, two feasible therapies and pathways in managing brain tumors in humans have been established: either by stabilizing p53 conformation as indicated in studies using PRIMA-1 (V), ((2,2-bis(hydroxymethyl)-1-azabicyclo [2.2.2]octan-3-one)) [14], or by inhibiting, or disrupting p53 interaction with MDM2 ligand, as indicated in the experiments using Nutlin-3, MI-219 (VI) [17], but also various vegetal ceramides [16], curcumin [30,55], chalcones [17,58,59], and other compounds found in the specialized catalogs [60].